Poor
Not Aligned
Patient Risk:
Moderate
Summary
Several safety-relevant and core labeling elements (notably indication text, dosing/administration, contraindications, boxed warnings, and key precautions) are not verifiable because the provided FDA label excerpts omit those sections. Multiple mechanism/clinical-effect claims and all cost/patent claims are unsupported by the provided excerpts.
Category Scores
Accurate Statements
Taclonex is a combination of calcipotriene and betamethasone dipropionate.
11 DESCRIPTION: "Taclonex® Ointment contains calcipotriene hydrate and betamethasone dipropionate."
Calcipotriene is a synthetic vitamin D3 analog.
11 DESCRIPTION: "Calcipotriene hydrate is a synthetic vitamin D3 analogue."
Betamethasone dipropionate is a synthetic corticosteroid.
11 DESCRIPTION: "Betamethasone dipropionate is a synthetic corticosteroid."
Taclonex may be associated with application-site reactions including itching/pruritus and burning sensation.
6.1 CLINICAL STUDY EXPERIENCE: "Pruritis"; "Application site pruritus"; "Burning sensation" (as adverse events reported).
If skin irritation develops, treatment with Taclonex should be discontinued and appropriate therapy instituted.
5.7 Skin Irritation: "If irritation develops, treatment with Taclonex® Ointment should be discontinued and appropriate therapy instituted."
Unsupported Statements
Taclonex is a topical medication prescribed for the treatment of plaque psoriasis.
The provided label excerpts do not include Section 1 (INDICATIONS AND USAGE); therefore plaque psoriasis indication cannot be verified from the supplied text.
Betamethasone dipropionate is a potent corticosteroid.
The provided excerpts state it is a synthetic corticosteroid but do not use/justify the term "potent".
Calcipotriene works by slowing the growth of skin cells.
No such mechanism statement is present in the provided excerpts; Section 12.1 excerpt indicates the exact mechanisms in psoriasis vulgaris are unknown.
Betamethasone dipropionate reduces inflammation, redness, and itching.
The provided excerpts do not state these clinical effects; Section 12.1 excerpt states the exact mechanisms in psoriasis vulgaris are unknown.
Patients using Taclonex may experience application site reactions such as burning, itching, or stinging.
Burning sensation and pruritus are supported, but "stinging" is not explicitly present in the provided adverse event text.
Other potential side effects of Taclonex include skin irritation, dryness, redness, or peeling.
Skin irritation and redness/erythema are present, but "dryness" and "peeling" are not explicitly supported by the provided excerpts.
Prescription drug costs are influenced by insurance coverage.
No cost/coverage statements are present in the provided label excerpts.
Prescription drug costs are influenced by patient assistance programs.
No cost or patient assistance program statements are present in the provided label excerpts.
Prescription drug costs are influenced by whether generic versions are available.
No cost or generic-availability statements are present in the provided label excerpts.
Insurance plans typically cover prescription medications.
No insurance coverage statements are present in the provided label excerpts.
Out-of-pocket cost for patients can differ based on a specific plan's formulary, deductible, copay, and coinsurance.
No out-of-pocket/cost-sharing formulary/deductible/copay/coinsurance statements are present in the provided label excerpts.
Pharmaceutical manufacturers sometimes offer patient assistance programs to help eligible individuals afford their medications.
No patient assistance program statements are present in the provided label excerpts.
Patient assistance programs may provide discounts, coupons, or free medication for those who meet specific income or insurance requirements.
No patient assistance program details are present in the provided label excerpts.
Taclonex patents may expire over time.
No patent/expiration statements are present in the provided label excerpts.
Contradictions
Important Omissions
FDA-labelable contraindications and boxed warnings (Sections 4 and 3/4 depending on format) are not included in the provided excerpts, so safety-critical compliance cannot be assessed.
Importance:
High
Dosage and administration details (Section 2) are not included in the provided excerpts; frequency, maximum duration, and administration safety constraints cannot be verified.
Importance:
High
Complete warnings and precautions beyond skin irritation (Section 5), including any topical-use limitations, ocular risks, and other discontinuation guidance, are not included in the provided excerpts.
Importance:
Moderate
Specific population sections (e.g., pregnancy/lactation and pediatric guidance) are not included in the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some adverse-event types and irritation-discontinuation guidance are supported, multiple mechanism/clinical-effect assertions and all cost/patent statements are unsupported. Additionally, major safety labeling areas (contraindications, boxed warnings, dosing/administration, and population-specific warnings) are not present in the provided excerpts, limiting verification of safe use claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Core FDA label elements required to verify safe, on-label use (indications text, dosing/administration, contraindications, boxed warnings, and broader precautions) are missing from the provided excerpts; multiple claims are unsupported by the supplied label text (especially mechanisms and all cost/patent items).
Suggested Improvement
Restrict evaluation and claims to statements that are explicitly present in the provided FDA label excerpts. For mechanism and clinical-effect claims, use only the label-supported wording (e.g., the label’s statement about unknown exact mechanisms). For safety-critical sections (contraindications, boxed warnings, dosing/administration), obtain the missing label text before asserting compliance.